These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16785128)

  • 1. Isolated thrombocytopenia associated with hydroxyurea/deferiprone (L1) therapy in a sickle beta thalassemia patient.
    Sheikh-Taha M; Koussa S; Taher A
    Haematologica; 2006 Jun; 91(6 Suppl):ECR25. PubMed ID: 16785128
    [No Abstract]   [Full Text] [Related]  

  • 2. Deferiprone for thalassemia major.
    Rajeshwari K
    Indian Pediatr; 1999 Jul; 36(7):738-40. PubMed ID: 11203460
    [No Abstract]   [Full Text] [Related]  

  • 3. Febrile neutropenia and hemorrhagic stroke in a thalassemia major patient.
    Sheikh-Taha M; Koussa S; Inati A; Taher A
    Hemoglobin; 2007; 31(4):499-501. PubMed ID: 17994386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High doses of deferiprone may be associated with cerebellar syndrome.
    Beau-Salinas F; Guitteny MA; Donadieu J; Jonville-Bera AP; Autret-Leca E
    BMJ; 2009 Jan; 338():a2319. PubMed ID: 19164394
    [No Abstract]   [Full Text] [Related]  

  • 5. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
    Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
    Economou M; Printza N; Teli A; Tzimouli V; Tsatra I; Papachristou F; Athanassiou-Metaxa M
    Acta Haematol; 2010; 123(3):148-52. PubMed ID: 20185899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe Henoch-Schönlein purpura in a thalassemic patient under deferiprone treatment.
    Unal S; Gücer S; Kale G; Besbas N; Ozen S; Gümrük F
    Am J Hematol; 2008 Feb; 83(2):165-6. PubMed ID: 17712793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deferiprone-induced seizures in a patient with β-thalassemia major.
    Mallat NS; Beydoun A; Musallam KM; Koussa S; Taher AT
    Blood Cells Mol Dis; 2013 Aug; 51(2):94-5. PubMed ID: 23587452
    [No Abstract]   [Full Text] [Related]  

  • 9. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
    Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
    Olivieri NF; Brittenham GM; McLaren CE; Templeton DM; Cameron RG; McClelland RA; Burt AD; Fleming KA
    N Engl J Med; 1998 Aug; 339(7):417-23. PubMed ID: 9700174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deferiprone chelation therapy for thalassemia major.
    Galanello R; Campus S
    Acta Haematol; 2009; 122(2-3):155-64. PubMed ID: 19907153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arthropathy in thalassaemia patients receiving deferiprone.
    Berkovitch M; Laxer RM; Inman R; Koren G; Pritzker KP; Fritzler MJ; Olivieri NF
    Lancet; 1994 Jun; 343(8911):1471-2. PubMed ID: 7911181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurological Complications and Cataract in a Child With Thalassemia Major Treated With Deferiprone.
    Parakh N; Sharma R; Prakash O; Mahto D; Dhingra B; Sharma S; Chandra J
    J Pediatr Hematol Oncol; 2015 Oct; 37(7):e433-4. PubMed ID: 26165407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Posterior subcapsular opacity in two patients with thalassaemia major following deferiprone consumption.
    Mehdizadeh M; Nowroozzadeh MH
    Clin Exp Optom; 2009 Jul; 92(4):392-4. PubMed ID: 19515094
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmaco/ferrokinetic-related pro-oxidant activity of deferiprone in beta-thalassemia.
    Jirasomprasert T; Morales NP; Limenta LM; Sirijaroonwong S; Yamanont P; Wilairat P; Fucharoen S; Chantharaksri U
    Free Radic Res; 2009 May; 43(5):485-91. PubMed ID: 19353420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of oral iron chelator deferiprone in young thalassaemics.
    Naithani R; Chandra J; Sharma S
    Eur J Haematol; 2005 Mar; 74(3):217-20. PubMed ID: 15693791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea therapy in 49 patients with major beta-thalassemia.
    Zamani F; Shakeri R; Eslami SM; Razavi SM; Basi A
    Arch Iran Med; 2009 May; 12(3):295-7. PubMed ID: 19400608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
    Pantalone GR; Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Romeo MA; Magnano C; Caruso V; Argento C; Gerardi C; Campisi S; Violi P; Malizia R; Cianciulli P; Rizzo M; D'Ascola DG; Quota A; Prossomariti L; Fidone C; Rigano P; Pepe A; D'Amico G; Morabito A; Gluud C
    Hemoglobin; 2011; 35(3):206-16. PubMed ID: 21599433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to desferrioxamine and deferiprone and the impact of deferiprone co-prescription in thalassaemia major patients. Does the addition of deferiprone improve adherence?
    Kidson-Gerber G; Lindeman R
    Br J Haematol; 2008 Aug; 142(4):679-80. PubMed ID: 18537970
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.